MedTrace Logo

Endothelial Dysfunction Evaluation for Coronary Heart Disease Risk Estimation in Rheumatoid Arthritis (EDRA Study)

NCT02341066 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2016-02-26

No results posted yet for this study

Summary

To evaluate the contribution of the assessment of endothelial dysfunction (ED) in improving coronary hearth disease (CHD) risk stratification obtained by the Framingham risk score (FRS) in rheumatoid arthritis population (RA).

Conditions

Interventions

DEVICE

Endothelial Dysfunction evaluation by EndoPAT

Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).

Sponsors & Collaborators

  • Azienda Ospedaliero Universitaria di Cagliari

    collaborator OTHER

  • Complesso Integrato Columbus, Roma

    collaborator UNKNOWN

  • Azienda Ospedaliero Universitaria di Sassari

    lead OTHER

Principal Investigators

  • Gian Luca Erre, MD, PhD · Azienda Ospedaliero Universitaria di Sassari

Eligibility

Min Age
45 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02341066 on ClinicalTrials.gov